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Riuretic Use, Progressive Heart Failure,
nd Death in Patients in SOLVD
read with great interest the study by Domanski et al. (1) on
iuretic use and outcome of heart failure. The first question that
omes to mind is whether patients taking non–potassium-sparing
iuretics (PSDs) were sicker than patients taking PSDs consider-
ng the weak diuretic action of PSDs. The fact that 25% of patients
n the PSDs-only group were receiving beta-blockers is indicative
f a relatively “healthy” group. Thus, it might have been appro-
riate to exclude these patients from study. In the multivariate
nalysis, the investigators should consider including two variables
ndicative of the severity of heart failure, namely elevated jugular
enous distention and a third heart sound. These two clinical signs
ave previously been found in the Studies Of Left Ventricular
ysfunction (SOLVD) to be independently associated with ad-
erse outcome (2).
Thus, the issue of confounding by the severity of heart failure
ould be more adequately addressed by providing data on jugular
enous distention and a third heart sound and including them in
he multivariate analysis.
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e appreciate Dr. Ghali’s interest in our report and respond to his
pecific points as follows:
First, Dr. Ghali suggests excluding patients in the potassium-
paring diuretics (PSD)-only group on beta-blockers because they
re more healthy. In fact, beta-blocker use was included in the
ultivariate analysis in our study. To exclude them from the
nalysis is not justified, and, in fact, would represent a serious
ethodological error.
Second, the state of the disease is captured in the New York
eart Association (NYHA) functional class and in the ejection
raction included in the multivariate analysis. The presence or
bsence of a third heart sound and/or jugular venous distension is
ubject to substantial potential for ascertainment error and, weelieve, would be less reliable than the indicators of disease severity
rovided.
Finally, although only a prospective randomized study will offer
definitive answer, we believe that emerging data, such as the
ALES study with the PSD spironolactone, support our findings.
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ympathetic Nervous System
ctivation in Chagasic
atients With Congestive Heart Failure
he pathogenesis and the medical treatment of chronic Chagas’
isease are still subjects of intense controversy and research (1–5).
n the study by Roveda et al. published in the Journal (6), exercise
raining decreased sympathetic nervous system activation in pa-
ients with congestive heart failure. It should be pointed out that 5
f 16 patients were of chagasic etiology (31.25%). As stated by the
nvestigators, four of these patients were in the sedentary group
nd one in the exercise group. The former continued to have
ncreased sympathetic activity, whereas the latter showed a signif-
cant and beneficial decrease in the degree of sympathetic activa-
ion. Moreover, resting muscle sympathetic nerve activity was now
imilar to trained healthy control subjects.
These findings raise several relevant questions: Was the degree
f sympathetic nervous system activation of chagasic patients
imilar to that of non-chagasic patients? If so, chagasic patients
ith congestive heart failure do not have sympathetic dysautono-
ia (7–9). Also, are the mechanisms responsible for sympathetic
ctivation and exercise training-induced beneficial effects in cha-
asic patients similar to those of non-chagasic patients (10,11)?
inally, do these results indirectly suggest that chagasic patients
ith congestive heart failure would benefit from therapeutic
trategies that antagonize sympathetic nervous system activation
12)?
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